NCT03748524已完成早期 1 期
Washington University (WU) 321: Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine: Fine Needle Aspiration (FNA) and Bone Marrow Aspiration (BMA)
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Determine the percentage of subjects achieving seroconversion
研究概览
简要总结
Immunization with the inactivated influenza vaccine with blood samples collected at 7 visits (baseline, day 7, 14, 28, 60, 90 and 180, fine needle aspiration (FNAs) from axillary lymph nodes at baseline, days, 4, 14, 28, 60 and 180. BMA at baseline, days 28 and 180.
详细描述
IM Immunization with the inactivated influenza vaccine with blood samples collected at 7 visits (baseline, day 7, 14, 28, 60, 90 and 180, fine needle aspiration (FNAs) from axillary lymph nodes at baseline, days, 4, 14, 28, 60 and 180. BMA at baseline, days 28 and 180.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able to understand and give informed consent
- •Capable of attending all study visits according to the study schedule.
- •Males or females between the ages of 18 to 50 (inclusive).
- •Are in good health, as determined by medical history and targeted physical exam related to this history.
- •Participants agree not to take any vaccines in the first 60 days after receipt of the influenza vaccine
- •The following laboratory values obtained within 14 days prior to entry..
- •Absolute neutrophil count (ANC) ≥750 cells/mm3
- •Hemoglobin ≥11.0 g/dL for men and ≥10.0 g/dL for women
- •Platelet count ≥100,000/mm3
- •Creatinine clearance ≥60 mL/min estimated by the Cockcroft-Gault equation
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (SGPT) ≤5.0 times upper limit of normal (ULN)
- •Willing to:
- •give FNA specimens for the study. (even if he/she are not willing to give bone marrow aspirates (for any reason), they can be enrolled)
- •give bone marrow aspirates, but we cannot locate axillary lymph nodes
- •give both FNA and BMA specimens
排除标准
- •History influenza vaccination for the last three years.
- •Coagulopathy (primary or iatrogenic) which would contraindicate FNA
- •Any history of allergy to eggs, chicken or gelatin or to any previous influenza vaccine
- •Have an acute illness within 72 hours before vaccination.
- •A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study.
- •History of HIV infection, Hepatitis B or Hepatitis C infection
- •History of any chronic medical conditions that are considered progressive (ex, diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal diseases and uncontrolled hypertension).
- •History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the study.
- •Have taken oral or parenteral corticosteroids of any dose within 30 days before study vaccination.
- •Have taken high-dose inhaled corticosteroids within 30 days before study vaccination.
- •Autoimmune disorders; mild autoimmune disorders such as eczema is not exclusion after assessment by the investigator.
- •Recipient of a blood products or immune globulin product within 42 days of the vaccination visit.
- •Pregnant women and nursing mothers or women who are planning to become pregnant for the study duration.
- •Have received any licensed live vaccine within 30 days or any licensed inactivated vaccine within 14 days prior to study vaccination.
- •Have planned vaccination with any vaccine during first 60 days of study participation.
- •Have received immunoglobulin or other blood products, with the exception of Rho D immunoglobulin, within 90 days prior to study vaccination.
- •Have donated blood or blood products within 30 days before study vaccination, plan to donate blood at any time during the duration of subject study participation, or plan to donate blood within 30 days after the last blood draw.
- •Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial.
研究组 & 干预措施
Single Influenza Vaccine
Experimental
Single Influenza Vaccine,Quadrivalent
干预措施: Influenza Vaccine (Drug)
结局指标
主要结局
Determine the percentage of subjects achieving seroconversion
时间窗: 0 and day 28
Change in serum hemagglutination-inhibition (HAI) antibody titers between day 0 to day 28
次要结局
- Determine the frequency of vaccine-induced responses(Day7)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Study of the antibody titer by Influenza vaccination in Rheumatoid Arthritis patients treated with MTX and Biological agentsRheumatoid ArthritisJPRN-UMIN000010405agoya Medical Center, National Hospital Organization in JAPA170
已完成
2 期
A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy AdultsSwine-origin A/H1N1 InfluenzaInfluenzaNCT01089660Sanofi Pasteur, a Sanofi Company202
已完成
不适用
Research on influenza vaccine immunogencity in infants.influenzaJPRN-C000000241The Research Foundation for Microbial Diseases of Osaka University200
已完成
不适用
Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the SeasonInfluenzaNCT04530786University of Wisconsin, Madison100
已完成
4 期
Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong KongInfluenza, HumanNCT03330132The University of Hong Kong1,861